The Recall Desk

Manufacturer

Upsher Smith Laboratories, Inc.

6 recalls in our database name Upsher Smith Laboratories, Inc. as the manufacturing or recalling firm.

What the numbers show

Total
6
Critical
0
Severe
1
Most recent
2019-08-28

Of the 6 recalls from Upsher Smith Laboratories, Inc. we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 1 (17%) are Severe.

About this listing

The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.

Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.

1–6 of 6

  • ModerateFDA (Drugs)·D-0281-2019·2018-10-31

    Upsher Smith Recalls Bumetanide Tablets for Unspecified Degradation Product

    Upsher Smith Laboratories is recalling 29,080 bottles of Bumetanide 2 mg tablets because the product failed impurity specifications for an unspecified degradation product.

    Product
    BUMETANIDE — BUMETANIDE (BUMETANIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • LowFDA (Drugs)·D-1255-2014·2014-04-30

    Upsher Smith Recalls Oxandrolone Tablets Due to Missing Primary Labels

    Upsher Smith Laboratories is recalling 36 bottles of Oxandrolone Tablets, USP, 10 mg, because they were packaged without primary labels.

    Product
    Oxandrolone Tablets, USP, 10 mg, Rx Only, C-III, 60-count bottle, Manufactured for: Upsher-Smith Labs, Minneapolis, MN 55447, by: Pharmaceutics International, Inc., Hunt Valley, MD 21031, NDC 0245-0272-06
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-160-2013·2013-02-20

    Upsher Smith Recalls Propranolol Hydrochloride Capsules for Dissolution Failure

    Upsher Smith Laboratories is recalling 60 bottles of Propranolol Hydrochloride Extended-release Capsules, 80 mg, due to failed dissolution test requirements.

    Product
    Propranolol Hydrochloride Extended-release Capsules, USP, 80 mg, 100 Capsules, Rx only, Manufactured for Upsher Smith Laboratories, Inc Minneapolis MN 55447 --- NDC 0245-0085-11, UPC 3 0245-0085-11 9
    Category
    Drug
    Distribution
    2 states
  • LowFDA (Drugs)·D-127-2013·2013-01-23

    Upsher Smith Recalls Divalproex Sodium Tablets Due to Labeling Error

    Upsher Smith is recalling 11,316 bottles of Divalproex Sodium Delayed-Release Tablets because some labels are missing the color-coded strength indicator.

    Product
    Divalproex Sodium Delayed-Release Tablets, USP, 500 mg Valproic Acid Activity, 100-count tablets per bottle, Rx only, Manufactured by Upsher-Smith Laboratories, Inc., Minneapolis, MN 55447, NDC 0245-0182-11.
    Category
    Drug
    Distribution
    Distributed nationwide

About this company

Community-sourced company facts from Wikidata, not from any recall agency. This is background on the corporate entity — it says nothing about the recall(s) listed on this page, which come from the agency source notice above.

Upsher-Smith Laboratories

American pharmaceutical company

Country
United States
Founded
1919
Parent company
Bora Pharmaceuticals

Official website

Source: Wikidata (Q7899254), licensed CC0. Wikidata is community-edited and may not reflect the current corporate structure.